New cocktail of cancer drugs shows promise for tough lymphoma
NCT ID NCT04970901
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-stage study is testing a drug called loncastuximab tesirine (ZYNLONTA) combined with other anti-cancer agents in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find safe doses and see how well the combinations work. About 200 adults aged 18 and older who have tried at least two prior treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- loncastuximab tesirine (ZYNLONTA) combined with polatuzumab vedotin, glofitamab, mosunetuzumab, or obinutuzumab
- What this could lead to
- If it works, this could point toward a new combination treatment for people with hard-to-treat B-cell non-Hodgkin lymphoma.
- What could go wrong
- This is a very early (Phase 1) trial with only 200 participants, so it may not lead to a proven treatment. The drug combinations can cause serious side effects, and it is not yet known if they will work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny Health Network - West Penn Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
Bergamo, 24127, Italy
-
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia
Brescia, 25123, Italy
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brown University Health - Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
Yvoir, B-5530, Belgium
-
Centro di Ricerche Cliniche - IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, 40138, Italy
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10027, United States
-
Complejo Asistencial Universitario de Salamanca - Hospital Clínico
Salamanca, 37007, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emily Couric Clinical Cancer Center
Charlottesville, Virginia, 22903, United States
-
Fakultni nemocnice Ostrava
Ostrava, 708 52, Czechia
-
Fakultni nemocnice v Motole
Prague, 150 06, Czechia
-
Fakultní Nemocnice Královské Vinohrady
Prague, 100 34, Czechia
-
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)
Nashville, Tennessee, 37203, United States
-
Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital Universitari i Politècnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
Barcelona, 08908, Spain
-
Istituto Europeo di Oncologia
Milan, 20141, Italy
-
Memorial Cancer Institute - Memorial Hospital West
Pembroke Pines, Florida, 33028, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
Mission Cancer + Blood - Mission Cancer Foundation
Des Moines, Iowa, 50309, United States
-
NEXT Virginia (Virginia Cancer Specialists)
Fairfax, Virginia, 22031, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 7LE, United Kingdom
-
Penn Medicine - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Scripps Health - Prebys Cancer Center
San Diego, California, 92103, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
The Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, 30342, United States
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
University of California San Francisco - Fresno Center for Medical Education and Research
Clovis, California, 93611, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- New drug combo aims to tackle Hard-to-Treat lymphoma
- New daily pill aims to tackle Hard-to-Treat lymphoma
- New drug candidate SHR-3079 targets Hard-to-Treat lymphoma